Condition: Inflammatory Disorder · Autoimmune · Sponsor: University Hospital, Basel, Switzerland
This study is an Investigator-initiated, placebo-controlled, multicenter noninferiority trial, comparing rapid termination of systemic glucocorticoid treatment with a tapering regime over 4 weeks.
This description comes directly from the study's public registry record.
Jonas Rutishauser, Prof MD · +41-56-486 25 14 · j.rutishauser@unibas.ch
Always discuss trial participation with your own doctor first.
| University Hospital Frankfurt | Frankfurt, Germany | Recruiting |
| University Hospital Würzburg | Würzburg, Germany | Recruiting |
| Departement of Internal Medicine, Kantonsspital Aarau | Aarau, Switzerland | Recruiting |
| Kantonsspital Baden | Baden, Switzerland | Recruiting |
| Endocrinology/Diabetology/Metabolism; University Hospital Basel | Basel, Switzerland | Terminated |
| St. Claraspital Basel | Basel, Switzerland | Recruiting |
| Department of Rheumatology, Immunology, and Allergology, Inselspital | Bern, Switzerland | Terminated |
| Division of Gastroenterology, Spital Bülach AG | Bülach, Switzerland | Terminated |
| Kantonsspital Frauenfeld | Frauenfeld, Switzerland | Recruiting |
| Geneva University Hospitals | Geneva, Switzerland | Recruiting |
| Center for Primary Health Care,University of Basel, Kantonsspital Baselland | Liestal, Switzerland | Terminated |
| Internal Medicine, Kantonsspital Baselland/Liestal | Liestal, Switzerland | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03153527